Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/GSK3A_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/GSK3A_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GSK3A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/GSK3A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GSK3A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GSK3A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000756820 | Esophagus | ESCC | aging | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
GO:00357948 | Esophagus | ESCC | positive regulation of mitochondrial membrane permeability | 36/8552 | 43/18723 | 2.90e-07 | 4.20e-06 | 36 |
GO:003011117 | Esophagus | ESCC | regulation of Wnt signaling pathway | 194/8552 | 328/18723 | 5.39e-07 | 7.14e-06 | 194 |
GO:006007016 | Esophagus | ESCC | canonical Wnt signaling pathway | 180/8552 | 303/18723 | 9.15e-07 | 1.17e-05 | 180 |
GO:000206420 | Esophagus | ESCC | epithelial cell development | 136/8552 | 220/18723 | 9.50e-07 | 1.21e-05 | 136 |
GO:009734510 | Esophagus | ESCC | mitochondrial outer membrane permeabilization | 28/8552 | 32/18723 | 1.02e-06 | 1.29e-05 | 28 |
GO:006082817 | Esophagus | ESCC | regulation of canonical Wnt signaling pathway | 153/8552 | 253/18723 | 1.38e-06 | 1.67e-05 | 153 |
GO:190165319 | Esophagus | ESCC | cellular response to peptide | 208/8552 | 359/18723 | 1.68e-06 | 2.01e-05 | 208 |
GO:190268614 | Esophagus | ESCC | mitochondrial outer membrane permeabilization involved in programmed cell death | 33/8552 | 40/18723 | 1.80e-06 | 2.11e-05 | 33 |
GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
GO:0051402110 | Esophagus | ESCC | neuron apoptotic process | 148/8552 | 246/18723 | 3.08e-06 | 3.47e-05 | 148 |
GO:001810515 | Esophagus | ESCC | peptidyl-serine phosphorylation | 184/8552 | 315/18723 | 3.22e-06 | 3.61e-05 | 184 |
GO:1901214111 | Esophagus | ESCC | regulation of neuron death | 186/8552 | 319/18723 | 3.35e-06 | 3.73e-05 | 186 |
GO:00380347 | Esophagus | ESCC | signal transduction in absence of ligand | 48/8552 | 65/18723 | 3.63e-06 | 3.97e-05 | 48 |
GO:00971927 | Esophagus | ESCC | extrinsic apoptotic signaling pathway in absence of ligand | 48/8552 | 65/18723 | 3.63e-06 | 3.97e-05 | 48 |
GO:0043434111 | Esophagus | ESCC | response to peptide hormone | 234/8552 | 414/18723 | 4.93e-06 | 5.21e-05 | 234 |
GO:190353315 | Esophagus | ESCC | regulation of protein targeting | 57/8552 | 81/18723 | 5.83e-06 | 6.03e-05 | 57 |
GO:19021108 | Esophagus | ESCC | positive regulation of mitochondrial membrane permeability involved in apoptotic process | 31/8552 | 38/18723 | 5.93e-06 | 6.10e-05 | 31 |
GO:003286918 | Esophagus | ESCC | cellular response to insulin stimulus | 124/8552 | 203/18723 | 6.63e-06 | 6.75e-05 | 124 |
GO:003286818 | Esophagus | ESCC | response to insulin | 156/8552 | 264/18723 | 7.21e-06 | 7.20e-05 | 156 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GSK3A | SNV | Missense_Mutation | | c.430N>G | p.Leu144Val | p.L144V | P49840 | protein_coding | tolerated(0.34) | benign(0.005) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
GSK3A | SNV | Missense_Mutation | rs750207489 | c.757N>A | p.Asp253Asn | p.D253N | P49840 | protein_coding | tolerated(0.54) | benign(0.286) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
GSK3A | SNV | Missense_Mutation | | c.710N>T | p.Ser237Phe | p.S237F | P49840 | protein_coding | deleterious(0.01) | probably_damaging(0.983) | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
GSK3A | SNV | Missense_Mutation | | c.758N>G | p.Asp253Gly | p.D253G | P49840 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-E9-A1R7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | fareston | SD |
GSK3A | insertion | Frame_Shift_Ins | novel | c.1322_1323insTACAGGCGTGAAC | p.Pro442ThrfsTer26 | p.P442Tfs*26 | P49840 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
GSK3A | insertion | Frame_Shift_Ins | novel | c.1320_1321insCCGCTTGGCCTCCTAAAGTGTTGGG | p.Ile441ProfsTer31 | p.I441Pfs*31 | P49840 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
GSK3A | SNV | Missense_Mutation | novel | c.787N>A | p.Asp263Asn | p.D263N | P49840 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GSK3A | SNV | Missense_Mutation | novel | c.616G>C | p.Ala206Pro | p.A206P | P49840 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-C5-A1M5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
GSK3A | SNV | Missense_Mutation | novel | c.288C>A | p.Asp96Glu | p.D96E | P49840 | protein_coding | tolerated(0.21) | benign(0.056) | TCGA-C5-A8ZZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Cisplatin | SD |
GSK3A | SNV | Missense_Mutation | | c.1264N>G | p.Leu422Val | p.L422V | P49840 | protein_coding | deleterious(0) | benign(0.377) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | Thiadiazolidindione derivative 2 | | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | PMID27828716-Compound-BIO-acetoxime | | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | CHIR-99021 | CHIR-99021 | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | inhibitor | 249565696 | | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | PHA-767491 | CHEMBL225519 | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | AR-A014418 | CHEMBL259850 | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | KENPAULLONE | KENPAULLONE | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | PMID27828716-Compound-17 | | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | Maleimides derivative 3 | | |
2931 | GSK3A | DRUGGABLE GENOME, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR, KINASE, ENZYME | | Indazole derivative 6 | | |